Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
2 hedge funds and large institutions have $442 invested in Avadel Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 202 closing their positions.
75.53% less ownership
Funds ownership: 75.53% → 0% (-76%)
99% less funds holding
Funds holding: 207 → 2 (-205)
100% less funds holding in top 10
Funds holding in top 10: 8 → 0 (-8)
100% less capital invested
Capital invested by funds: $1.6B → $442 (-$1.6B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 202
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$152M |
| 2 |
GJL
Gendell Jeffrey L
|
-$103M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$97.3M |
| 4 |
TAL
TIG Advisors LLC
New York
|
-$83.2M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$64.3M |
AVDL Hedge Fund Activity: Q1 2026 in Review
2 of the 8,192 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2026, worth a combined $442 — down 100% from $1.6B a quarter earlier.
Sellers outnumbered buyers: 202 funds closed out of AVDL and 0 opened new positions — a net loss of 202 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $152M sold.
- 2 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2026, down from 207 in Q4 2025.
- Funds reported $442 of Avadel Pharmaceuticals stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Avadel Pharmaceuticals positions in Q1 2026 and 202 closed out, a net change of -202 holders.
- The largest Avadel Pharmaceuticals seller in Q1 2026 was BlackRock, an estimated $152M sold.
Based on aggregated 13F filings for Q1 2026.